CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on creating and providing treatments for liver and various other chronic conditions. Its leading investigational drug is seladelpar (MBX-8025), a selective agonist for the peroxisome proliferator activated receptor delta, which is presently in a Phase III clinical trial for primary biliary cholangitis (PBC). This compound has also successfully completed a Phase 2b clinical study for patients suffering from nonalcoholic steatohepatitis (NASH). The company is also developing MBX-2982, currently in a Phase 2a clinical study to address hypoglycemia in individuals with type 1 diabetes. CymaBay has a licensing arrangement with ABW Cyclops SPV LP to support the development of seladelpar for PBC. Moreover, it holds a worldwide license from Janssen Pharmaceuticals, Inc., enabling it to research, develop, and commercialize agents targeting an undisclosed metabolic disease. Founded in 1988 and originally known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.